pegcetacoplan PNH
Selected indexed studies
- Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. (Int J Mol Sci, 2024) [PMID:39273426]
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (N Engl J Med, 2021) [PMID:33730455]
- Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. (J Blood Med, 2023) [PMID:37016661]
_Worker-drafted node — pending editorial review._
Connections
pegcetacoplan PNH is a side effect of
Sources
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. (2021) pubmed
- Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. (2023) pubmed
- Pegcetacoplan: First Approval. (2021) pubmed
- Pegcetacoplan versus Eculizumab in PNH. (2021) pubmed
- Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. (2024) pubmed
- Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. (2023) pubmed
- Pegcetacoplan versus Eculizumab in PNH. (2021) pubmed
- Pegcetacoplan versus Eculizumab in PNH. (2021) pubmed
- Three Years On: The Role of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) since Its Initial Approval. (2024) pubmed
- Pegcetacoplan versus Eculizumab in PNH. Reply. (2021) pubmed